(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, here ; for the Morning News Call newsletter, here ) Wall Street extended its gains into the second trading day of the new year, supported by consumer discretionary stocks, as investors awaited minutes of the Federal Reserve's December meeting where it raised interest rates.
Dow Jones industrial average futures were up 0.30 percent at 19,857, S&P 500 futures were up 0.48 percent at 2,263.25 and Nasdaq 100 futures were up 0.49 percent at 4,930.5.
** CYMABAY THERAPEUTICS INC, $2.48, +30.53 pct
The drug developer inked a licensing deal for development and commercialization of the company’s gout drug in the U.S. with Kowa Pharmaceuticals America, a unit of privately held Japanese multinational Kowa Co Ltd.
** TESLA MOTORS, $225.8, +4.06 pct
The electric car maker has started mass production of lithium-ion battery cells at its gigafactory in Nevada along with Japan’s Panasonic Corp.
** OCULAR THERAPEUTIX INC, $8.69, +4.45 pct
The eye drug developer announced additional positive secondary goal results from its most recent successful late-stage study of Dextenza, the company’s treatment for post-operative eye pain.
** BELLEROPHON THERAPEUTICS INC, $0.6298, +16.39 pct
Bellerophon said the U.S. FDA had agreed to the company’s proposed changes to the late-stage development of its pulmonary arterial hypertension (PAH) treatment, INOpulse, a nitric-oxide delivery device.
** EVOKE PHARMA INC, $2.66, +28.50 pct
Evoke can still chart a path to U.S. approval for its treatment for diabetic gastroparesis, despite a failed late-stage study, additional data from the trial shows
** BONANZA CREEK ENERGY INC, $1.31, +33.27 pct
The company initiated prepackaged Chapter 11 proceedings pursuant to a restructuring support agreement.
** NIVALIS THERAPEUTICS INC, $2.39, +8.39 pct
The company said its board has initiated a process to explore and review a range of strategic alternatives.
** CERNER CORP, $48.06, -2.71 pct
UBS cut its price target on the company’s stock to $52 from $60, citing uncertainty around the potential repeal of Affordable Care Act, or Obamacare, and has raised questions over near-term hospital capex budgets.
** WEIGHT WATCHERS INTERNATIONAL INC, $13.35, +20.49 pct
Sidoti raised its price target on the stock to $28 from $25.
** SOCIAL REALITY INC, $4.96, -19.22 pct
The online advertising company said that it entered into a securities purchase agreement with certain fundamental institutional investors.
** GENERAL MOTORS CO, $36.99, +5.23 pct
** FORD MOTOR CO, $13.235, +5.12 pct
GM said that total U.S. sales in December were 319,108, up 10 percent from last year.
Ford said its sales totaled 239,854 vehicles, up 0.3 percent.
** O2MICRO INTERNATIONAL LTD, $2.2735, +20.29 pct
The company raised its fourth-quarter revenue estimate to $15.4 million-$15.9 million from $14.7 million-$15.6 million due to increased demand for high-end TV and power tools.
** UNIFIRST CORP, $138.75, -4.31 pct
The company reported smaller-than-expected quarterly results and modified 2017 expectations, citing higher expenses. UniFirst said first-quarter growth was affected by the loss of “uniform wearers and customers in North American energy-dependent markets”.
** SHAKE SHACK INC, $38.78, +7.33 pct
The company will replace chemical company Chemours on the S&P 600 SmallCap index after close of trading on Wednesday.
** NIMBLE STORAGE INC, $8.12, +3.57 pct
Maxim raised its price target on the stock.
** AGILE THERAPEUTICS INC, $2.6399, -47.20 pct
At least two brokerages cut their price targets on the stock after results from the late-stage trial of the company’s once-weekly contraceptive patch, Twirla, disappointed investors.
** GILEAD SCIENCES INC, $76.59, +3.28 pct
The company has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology.
** ENCANA CORP, $12.84, +7.54 pct
The oil and natural gas producer said it expects margins in 2017 to exceed its previous target on lower costs and an expected rise in output in the second half of the year. (Compiled by Rishika Sadam in Bengaluru; Editing by Maju Samuel)